Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment Efficacy and Prognostic Factors for Huge HCC Based on Barcelona Clinic Liver Cancer Staging

  • Zhang, Zhi-Ming (Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University) ;
  • Zhang, Yu-Mei (Department of Chemotherapy, The Affiliated Tumor Hospital of Guangxi Medical University) ;
  • Gao, Sheng (Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University) ;
  • Yuan, Wei-Ping (Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University) ;
  • Zhao, Yin-Nong (Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University) ;
  • Xiang, Bang-De (Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University) ;
  • Wu, Fei-Xiang (Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University) ;
  • Wu, Guo-Bin (Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University) ;
  • Liu, Jian-Yong (Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University)
  • Published : 2014.11.06
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To explore the most appropriate treatment for patients with hepatocellular cancer (HCC) >10 cm by using the Barcelona Clinic Liver Cancer (BCLC) classification. Materials and Methods: A total of 124 HCC patients undergoing surgery were selected. Disease-free survival (DFS), overall survival (OS) and prognostic factors were respectively assessed. Results: This study showed that the cumulative 1-, 3-, 5-year survival rates were 79.7%, 59.8% and 41.6% in BCLC-A patients, 76.2%, 9.5% and 0% in BCLC-B patients and 44.9%, 0% and 0% in BCLC-C patients, respectively. The 1-, 3-, 5-year DFS rates were 49%, 24.5% and 9.1% in BCLC-A patients, 7.5%, 0% and 0% in BCLC-B patients, respectively. No BCLC-C patients survived 1 year after surgery. Multivariate analysis indicated that hepatitis B surface antigen (HBsAg), vascular invasion, intra-hepatic metastasis, curative resection, tumor rupture and pathologic differentiation were independent prognostic factors. Conclusions: Surgery is effective and safe for patients with HCC >10 cm with sufficient hepatic reserve.

Keywords

References

  1. Arai T, Akita S, Sakon M, et al (2014). Hepatocellular carcinoma associated with sarcoidosis. Int J Surg Case Rep, 5, 562-5. https://doi.org/10.1016/j.ijscr.2014.06.018
  2. Bagi CM, Gebhard DF, Andresen CJ (2012). Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models ofhepatocellular carcinoma. Eur J Gastroenterol Hepatol, 24, 563-74. https://doi.org/10.1097/MEG.0b013e328350916f
  3. Cheng XP, Zhang ZW (2009). Surgical treatment strategy of large and huge hepatocellular carcinoma. Chin J Operative Proced General Surg, 3, 702-6.
  4. Chow KC, Tang CN, Lai EC, et al (2013). Curative treatment for recurrent tumour implantation after ruptured hepatocellular carcinoma. Hong Kong Med J, 19, 82-4.
  5. Graf D, Vallbohmer D, Knoefel WT, et al (2014). Multimodal treatment of hepatocellular carcinoma. Eur J Intern Med, 25, 430-7. https://doi.org/10.1016/j.ejim.2014.03.001
  6. Hironori K, Masaru T, Yuichiro O, et al (2008). Laparoscopyassisted hepatectomy for giant hepatocellular carcinoma. Surg Laparosc Endosc Percutan Tech, 18, 127-31. https://doi.org/10.1097/SLE.0b013e318158237b
  7. Jin YJ, Lee JW, Choi YJ, et al (2014). Surgery versus transarterial chemoembolization for solitary large hepatocellular carcinoma of BCLC stage A. J Gastrointest Surg, 18, 555-61. https://doi.org/10.1007/s11605-013-2440-x
  8. Joshita S, Yoshizawa K, Sano K, et al (2010). A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome. Intern Med, 49, 991-4. https://doi.org/10.2169/internalmedicine.49.3153
  9. Li GH, Hong ZX, Zhang KM (2012). Surgical treatment of huge hepatocellular carcinoma. J Mod Oncol, 20, 1495- 7.
  10. Li SH, Guo ZX, Xiao CZ, et al (2013). Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection. Asian Pac J Cancer Prev, 14, 4759-63. https://doi.org/10.7314/APJCP.2013.14.8.4759
  11. Li SL, Su M, Peng T, et al (2013). Clinicopathologic characteristics and prognoses for multicentric occurrence and intrahepatic metastasis in synchronous multinodular hepatocellular carcinoma patients. Asian Pac J Cancer Prev, 14, 217-23. https://doi.org/10.7314/APJCP.2013.14.1.217
  12. Maida M, Orlando E, Camma C, et al (2014). Staging systems of hepatocellular carcinoma: areviewofliterature. World J Gastroenterol, 20, 4141-50. https://doi.org/10.3748/wjg.v20.i15.4141
  13. Que JY, Lin LC, Lin KL, et al (2014). The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities. Radiat Oncol, 9, 120. https://doi.org/10.1186/1748-717X-9-120
  14. Ren YQ, Han JQ, Cao JB, et al (2012). Association of MDR1 gene polymorphisms with susceptibility to hepatocellular carcinoma in the Chinese population. Asian Pac J Cancer Prev, 13, 5451-4. https://doi.org/10.7314/APJCP.2012.13.11.5451
  15. Scaggiante B, Kazemi M, Pozzato G, et al (2014). Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials. World J Gastroenterol, 20, 1268-88. https://doi.org/10.3748/wjg.v20.i5.1268
  16. Shin YJ, Kim MS, Yoo SY, et al (2010). Pilot study of stereotactic body radiotherapy for huge hepatocellular carcinoma unsuitable for other therapies. Tumori, 96, 65-70.
  17. Tsoulfas G, Mekras A, Agorastou P, et al (2012). Surgical treatment for large hepatocellular carcinoma: does size matter? ANZ J Surg, 82, 510-7. https://doi.org/10.1111/j.1445-2197.2012.06079.x
  18. Wang ZJ, Wang MQ, Duan F, et al (2013). Clinical application of transcatheter arterial chemoembolization combined with synchronous C-arm cone-beam CT guided radiofrequency ablation in treatment of large hepatocellular carcinoma. Asian Pac J Cancer Prev, 14, 1649-54. https://doi.org/10.7314/APJCP.2013.14.3.1649
  19. Yang J, Li C, Wen TF, et al (2014). Is hepatectomy for huge hepatocellular carcinoma (${\geq}$ 10cm in diameter) safe and effective? A single-center experience. Asian Pac J Cancer Prev, 15, 7069-77. https://doi.org/10.7314/APJCP.2014.15.17.7069
  20. Yang L, Xu J, Ou D, et al (2013). Hepatectomy for Huge Hepatocellular Carcinoma: Single Institutes Experience. World J Surg, 37, 2189-96. https://doi.org/10.1007/s00268-013-2095-5
  21. Yang LY, Fang F, Yang H (2010). Surgical resection of solitary huge hepatocellular carcinoma. Chin J Pract Surg, 30, 662-4.
  22. Yamashita Y, Taketomi A, Shirabe K, et al (2011). Outcomes of hepatic resection for huge hepatocellularcarcinoma (${\geq}$ 10cm in diameter). J Surg Oncol, 104, 292-8. https://doi.org/10.1002/jso.21931
  23. Zhang Y, Zhang WL, Huang DS, et al (2013). Clinical efficacy and prognosis factors for advanced hepatoblastoma in children: a 6-year retrospective study. Asian Pac J Cancer Prev, 14, 4583-9. https://doi.org/10.7314/APJCP.2013.14.8.4583
  24. Zhong NB, Lv GM, Chen ZH (2014). Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (${\geq}$ 10 cm)hepatocellular carcinomas: A clinical study. Mol Clin Oncol, 2, 839-844.
  25. Zhang ZW, Cheng XP (2008). Techniques for large hepatic resection. J Hepatobil Surg, 16, 6-7.

Cited by

  1. Overexpression of Klotho suppresses liver cancer progression and induces cell apoptosis by negatively regulating wnt/β-catenin signaling pathway vol.13, pp.1, 2015, https://doi.org/10.1186/s12957-015-0717-0
  2. Systematic Review of Single Large and/or Multinodular Hepatocellular Carcinoma: Surgical Resection Improves Survival vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5541
  3. Plasma Nuclear Factor Kappa B and Serum Peroxiredoxin 3 in Early Diagnosis of Hepatocellular Carcinoma vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1657
  4. The High Expressed Serum Soluble Neural Cell Adhesion Molecule, a High Risk Factor Indicating Hepatic Encephalopathy in Hepatocelular Carcinoma Patients vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3131
  5. Risk factors for the Long-Term Efficacy, Recurrence, and Metastasis in Small Hepatocellular Carcinomas vol.72, pp.2, 2015, https://doi.org/10.1007/s12013-015-0514-y
  6. Inhibits Growth and Promotes Invasion and Extracellular Matrix Degradation in Hepatocellular Carcinoma Cells vol.15, pp.5, 2016, https://doi.org/10.1021/acs.jproteome.5b01125
  7. Transarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.473